L’outil de licence Creative Commons du formulaire de soumission ne fonctionne pas actuellement. Pour ajouter une licence CC à votre thèse ou publication, contactez ruor@uottawa.ca après le dépôt. -- The Creative Commons licence tool in the submission form is currently unavailable. To apply a CC licence to your thesis or publication, contact ruor@uottawa.ca after the deposit.

Relative abundance of a gut-derived Lancefieldella parvula strain is associated with severe inflammation in IBD

En cours de chargement...
Vignette d'image

Nom de la revue

ISSN de la revue

Titre du volume

Éditeur

Résumé

Abstract Background Lancefieldella parvula (previously known as Atopobium parvulum) has been associated with inflammatory bowel disease (IBD); however, prior in vivo studies relied on an oral-derived reference strain rather than intestinal clinical isolates, limiting interpretation of its role in gut inflammation. To address this gap, we isolated a clinical strain of L. parvula (designated L. parvula TI19E08) from a mucosal luminal aspirate of an ulcerative colitis (UC) participant. We developed a strain-specific quantitative PCR assay to quantify its abundance across anatomical sites in treatment-naïve pediatric IBD participant (UC and Crohn’s disease (CD)) and examined its relationship with site-specific endoscopic inflammation severity. Results We demonstrated that the relative abundance of L. parvula TI19E08 increased with increasing local inflammation severity. In UC, both strain-specific and total L. parvula levels were strongly correlated with inflammation severity, particularly in the proximal colon. In CD patients, strain-level associations were most pronounced in the terminal ileum, which is consistent with the disease distribution. Conclusion This study characterizes an intestinal L. parvula isolate and demonstrates that strain-level expansion correlates with disease severity across IBD subtypes and anatomical regions. These findings identify L. parvula TI19E08 as a candidate mucosal marker of inflammation severity in IBD patients.

Description

Mots-clés

Citation

Gut Pathogens. 2026 Aug 14;18(1):84

Approbation

Évaluation

Complété par

Référencé par